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The c-Jun NH2-terminal kinase (JNK) signal transduction pathway causes increased gene expression
mediated, in part, by members of the activating transcription factor protein (AP1) group. JNK is therefore
implicated in the regulation of cell growth and cancer. To test the role of JNK in Ras-induced tumor formation,
we examined the effect of compound ablation of the ubiquitously expressed genes Jnk1 plus Jnk2. We report that
JNK is required for Ras-induced transformation of p53-deficient primary cells in vitro. Moreover, JNK is
required for lung tumor development caused by mutational activation of the endogenous KRas gene in vivo.
Together, these data establish that JNK plays a key role in Ras-induced tumorigenesis.
The c-Jun NH2-terminal kinase (JNK) is a member of the
MAP kinase group that is activated by cytokines/growth factors
and also by exposure to environmental stress (16). Targets of
the JNK pathway are represented, in part, by members of the
activator protein 1 (AP1) group of transcription factors, in-
cluding c-Jun, JunB, JunD, and related proteins (16). JNK can
phosphorylate the NH2-terminal activation domain of these
molecules to promote increased transcription activity (16).
Moreover, JNK activation causes increased expression of Jun
family proteins (47). JNK therefore acts as a major physiolog-
ical regulator of AP1-dependent gene expression (16). It is
established that AP1-dependent gene expression can contrib-
ute to cell proliferation (50). Consequently, the JNK signal
transduction pathway may increase cell proliferation, and dys-
regulated JNK signaling may contribute to cancer.
The role of JNK in cancer has been studied using mouse
models. Two of the genes that encode JNK are expressed
ubiquitously (Jnk1 and Jnk2), and a third gene (Jnk3) is pri-
marily expressed in the nervous system (16). Studies using
Jnk1/ mice and Jnk2/ mice have demonstrated that JNK
can cause both positive and negative changes in tumor devel-
opment (16, 48). Thus, compared with wild-type mice, Jnk1/
mice exhibit decreased (and Jnk2/ mice exhibit increased)
carcinogen-induced skin cancer (11, 42). Moreover, carcino-
gen-induced hepatocellular carcinoma (28) and Bcr-Abl-in-
duced lymphoma (25) are suppressed in Jnk1/ mice (but not
Jnk2/ mice). In contrast, studies of glioblastoma, prostate
cancer, and lung carcinoma cell lines have identified important
roles for JNK2 (but not JNK1) (6, 13, 41, 53). Together, these
data confirm that JNK may play a role in cancer development,
but the relative roles of the JNK1 and JNK2 isoforms are
unclear.
It is established that the Jnk1 and Jnk2 genes exhibit partially
redundant functions (14, 15, 30, 46). Studies of compound
mutants with ablation of both ubiquitously expressed Jnk genes
are therefore required. These studies have been compromised
by the early embryonic lethal phenotype of Jnk1/ Jnk2/
mice (34). Nevertheless, Jnk1/ Jnk2/ murine embryonic
fibroblasts (MEF) have been prepared. These cells exhibit an
early senescence phenotype that is caused by engagement of
the p53 tumor suppressor pathway (14, 46). Immortalized wild-
type and JNK-deficient fibroblasts have been isolated using the
3T3 protocol that disrupts the p53 pathway (32). Retroviral
transduction assays with ectopic expression of activated Ras
demonstrated that both wild-type (WT) and JNK-deficient 3T3
cells can exhibit properties of transformed cells (32). JNK may
therefore not be required for Ras-induced transformation, but
this conclusion is subject to a number of important caveats. It
is likely that the 3T3 immortalization protocol does not cause
the same genetic alterations in both WT MEF and Jnk1/
Jnk2/ MEF. Moreover, these studies of 3T3 cells expressing
ectopic Ras may not be informative for understanding the
mechanism of epithelial cell tumor formation by mutational
activation of the endogenous KRas gene.
The purpose of this study was to test the requirement of JNK
for Ras-induced tumorigenesis. First, we examined whether
JNK is required for the Ras-induced transformation of primary
MEF with a defined genetic background. Second, we examined
the requirement of JNK for epithelial cell transformation using
an established model of lung cancer in mice. We report that
JNK is critically required for Ras-induced transformation of
MEF in vitro and for Ras-induced lung tumor formation in
vivo.
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Mice. We have described Jnk1/ mice (19), Jnk2/ mice (52), mice with con-
ditional expression of Jnk1 (14), and mice with conditional expression of KRasG12D
(29). Mice with Trp53 gene ablation (18) were provided by Stephen Jones, University
of Massachusetts Medical School. Mice with conditional expression of Trp53 (36)
were obtained from the Jackson Laboratory (strain B6.129P2-Trp53tm1Brn/J [stock
number 008462]). Mice expressing 4-hydroxy-tamoxifen-stimulated Cre (2) were ob-
tained from the Jackson Laboratory [strain B6;129-Gt(ROSA)26Sortm1(cre/ERT)Nat/J
(stock number 004847)]. The mice used in this study were backcrossed to the
C57BL/6J strain (Jackson Laboratories) and were housed in a facility accredited
by the American Association for Laboratory Animal Care (AALAC). The In-
stitutional Animal Care and Use Committee (IACUC) of the University of
Massachusetts approved all studies using animals.
Genotype analysis. Genotype analysis was performed by PCR using genomic
DNA as the template. The Jnk1LoxP (1.1-kb) and Jnk1 (0.4-kb) alleles were
identified using the amplimers 5-CCTCAGGAAGAAAGGGCTTATTTC-3
FIG. 1. Growth properties of Trp53/ Jnk1/ Jnk2/ embryonic fibroblasts. (A) Loss of contact growth inhibition in Trp53/ MEF cultures
is prevented by disruption of Jnk1 plus Jnk2. Wild-type (WT), Trp53/, and Trp53/ Jnk/ MEF were examined using phase-contrast
microscopy. Representative images are shown of cells growing in sparse (top) or confluent (bottom) culture conditions. (B) Growth of Trp53/
cells in low serum concentrations is prevented by disruption of Jnk1 plus Jnk2. WT, Trp53/, and Trp53/ Jnk/ MEF were plated on day 0
(D  0) and cultured for 7 days (D  7) in medium supplemented with different concentrations of serum. Relative cell numbers were measured
by staining with crystal violet. The data are presented as means  standard deviations (n  5) and are representative of results from three
independent experiments. Statistically significant differences (P  0.01) between WT MEF and mutant MEF are indicated with an asterisk. (C,
D) Soft agar colony formation by Trp53/ MEF requires JNK. Cells were grown in soft agar supplemented with 10% serum. Colony formation
was assessed after 20 days. (C) Representative images are shown of colonies formed by WT, Trp53/, and Trp53/ Jnk/ cells. The number of
colonies (10 cells) formed by each cell type was counted and is shown in panel D. Statistically significant differences (P 0.01) between WT MEF
and mutant MEF are indicated with an asterisk.
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and 5-GAACCACTGTTCCAATTTCCATCC-3. The wild-type Jnk1 (460-bp)
and knockout Jnk1 (390-bp) alleles were identified using the amplimers 5-CG
CCAGTCCAAAATCAAGAATC-3, 5-GCCATTCTGGTAGAGGAAGTTT
CTC-3, and 5-CCAGCTCATTCCTCCACTCATG-3. The wild-type Jnk2
(400-bp) and knockout Jnk2 (270-bp) alleles were identified using the amplimers
5-GGAGCCCGATAGTATCGAGTTACC-3, 5-GTTAGACAATCCCAGA
GGTTGTGTG-3, and 5-CCAGCTCATTCCTCCACTCATG-3. The wild-
type Trp53 (320-bp) and knockout Trp53 (150-bp) alleles were identified using
the amplimers 5-GTGTTTCATTAGTTCCCCACCTTGAC-3, 5-ATGGGAG
GCTGCCAGTCCTAACCC-3, 5-GTGGGAGGGACAAAAGTTCGAGGC
C-3, and 5-TTTACGGAGCCCTGGCGCTCGATGT-3. The wild-type Trp53
(288-bp) and Trp53LoxP (370-bp) alleles were identified using the amplimers
5-AGCACATAGGAGGCAGAGAC-3 and 5-CACAAAAACAGGTTAAAC
CCAG-3. The Trp53 (612-bp) allele was identified using the amplimers 5-C
ACAAAAACAGGTTAAACCCAG-3 and 5-GAAGACAGAAAAGGGGAG
GG-3. The wild-type KRas (285-bp), KRasG12D (315-bp), and KRasLSL-G12D
(600-bp) alleles were identified using the amplimers 5-GGGTAGGTGTTGG
GATAGCTG-3 and 5-TCCGAATTCAGTGACTACAGATGTACAGAG-3.
The Rosa26 (600-bp) and Rosa26-CreERT (300-bp) alleles were identified using
the amplimers 5-GCGAAGAGTTTGTCCTCAACC-3, 5-GGAGCGGGAG
AAATGGATATG-3, and 5-AAAGTCGCTCTGAGTTGTTAT-3.
Tumor assays. Lung tumors were studied in mice with conditional expression
of KRasG12D. Lung-specific expression of KRasG12D was studied using calcium
phosphate precipitated adenovirus-Cre (Gene Transfer Vector Core, University
of Iowa; 2.5  107 PFU/mouse) and nasal instillation (29). The tumorigenic
potential of MEF was examined by subcutaneous injection of 2  105 cells in
12-week-old male C57BL/6J mice (Jackson Laboratories).
Cell culture. Primary mouse fibroblasts (embryonic day 11) were prepared and
cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
calf serum, 1% penicillin-streptomycin, and 1% glutamine (Invitrogen). All stud-
ies were performed using low-passage primary MEF (4 passages). Cre-medi-
ated gene ablation was performed by treating MEF with 1 	M 4-hydroxytamox-
FIG. 2. Effect of JNK deficiency on cadherin expression. (A) MEF prepared from Rosa26-CreERT
/ Trp53LoxP/LoxP KRas
/LSL-G12D mice
(Trp53/ KrasG12D mice) and Rosa26-CreERT
/ Trp53LoxP/LoxP KRas
/LSL-G12D Jnk1LoxP/LoxP Jnk2/ mice (Trp53/ KrasG12D Jnk/ mice) were
treated with 1 	M 4-hydroxy-tamoxifen (24 h). The MEF were examined by phase-contrast microscopy. (B) The expression of E-cadherin,
N-cadherin, OB-cadherin, and -tubulin in Trp53/ and Trp53/ Jnk/ MEF was examined by immunoblot analysis. The effect of activated Ras
was examined. (C) E-cadherin and N-cadherin expression was examined by immunofluorescence microscopy (green). DNA was stained with DAPI
(blue). (D) The expression of E-cadherin, Snail, and Slug mRNA by KRasG12D Trp53/ MEF and KRasG12D Trp53/ Jnk/ MEF was examined
by quantitative RT-PCR assays. The data presented are normalized for the amount of Gapdh mRNA in each sample (mean  SD; n  3).
Statistically significant differences (*, P  0.05; **, P  0.001) are indicated.
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ifen (24 h). Soft agar assays were performed using methods described previously
(32). Cell number was measured using a hemocytometer and by staining with
crystal violet (32).
Retroviral transduction assays. The retroviral vectors pWZL-Blast-E-cad-
herin and pWZL-Blast-dn-cadherin (39) were obtained from Addgene (numbers
18800 and 18804). A human Nox4 cDNA (10) was cloned by blunt-end ligation
into the EcoRI site of the retroviral vector pWZL-Blast. Recombinant retrovi-
ruses were prepared and employed for transduction assays in MEF (35) by using
selection with 5 	g/ml blasticidin (6 days).
Immunoblot analysis. Cell lysates were examined by probing with antibodies
to caspase 3 (Cell Signaling Technology), E-cadherin (Cell Signaling Technol-
ogy), JNK1/2 (BD Biosciences and R&D Systems), N-cadherin (BD Biosci-
ences), OB-cadherin (Santa Cruz Biotechnology), phospho-JNK (Cell Signaling
Technology), poly(ADP-ribose) polymerase (PARP; BD Biosciences), PCNA
(Invitrogen), and -tubulin (Sigma). Immune complexes were detected using
enhanced chemiluminescence (NEN).
ELISA. Multiplexed enzyme-linked immunosorbent assay (ELISA) was per-
formed using a Luminex 200 machine (Millipore). Cell lysates were probed using
the BioPlex phosphoprotein and total target assay kit to measure phosphorylated
and total JNK, extracellular signal-regulated kinase (ERK), p38, and AKT (Bio-
Rad).
RNA analysis. Quantitative reverse transcription (RT)-PCR assays (TaqMan)
of mRNA expression were performed using a model 7500 fast real-time PCR
machine (Applied Biosystems) with total RNA prepared with an RNeasy minikit
(Qiagen). The probes were Cdh1 (E-cadherin; Mm01247357_m1), Cyba (p22phox;
Mm00514478_m1), Nox4 (Mm00479246_m1 and Hs00276431_m1), Snai1
(Mm00441533_g1), and Snai2 (Slug; Mm00441531_m1) (Applied Biosystems).
The relative mRNA expression was normalized by measurement of the amount
of Gapdh mRNA in each sample by using TaqMan assays (4352339E; Applied
Biosystems).
Reactive oxygen species (ROS) assay. Cells grown on glass-bottom dishes
(MatTek) were pretreated (8 h) without (control) or with 1 	g/ml rotenone
(Sigma) or 2.5 	M diphenyleneiodonium chloride (DPI) (Sigma) and then in-
cubated with 10 	M 2,7-dichlorodihydrofluorescein diacetate (H2DCFDA)
(Invitrogen) for 1 h at 37°C. The cells were washed three times with phosphate-
buffered saline (PBS) and imaged using a fluorescence microscope (Zeiss Axio-
vert). Fluorescence intensity was measured using ImageJ software.
Immunofluorescence analysis. Cells grown on coverslips were washed with
PBS, fixed in 4% paraformaldehyde (15 min), washed with PBS, and then incu-
bated in blocking buffer (0.3% Triton-PBS-5% normal goat serum) for 1 h at
25°C. Incubation with primary antibodies (E-cadherin [Cell Signaling Technol-
ogy] and N-cadherin [BD Biosciences]) was performed in blocking buffer for 14 h
at 4°C. The cells were washed and incubated with secondary antibody (Alexa
Fluor 488-conjugated goat anti-mouse or anti-rabbit antibody [Invitrogen]) in
blocking buffer for 1 h at 25°C. The coverslips were washed in PBS and mounted
using VectaShield medium containing DAPI (4,6-diamidino-2-phenylindole)
FIG. 3. Role of E-cadherin in KRas-mediated transformation of control and JNK-deficient MEF. (A) KRasG12D Trp53/ MEF and KRasG12D
Trp53/ Jnk/ MEF were transduced with recombinant retroviruses that express E-cadherin (lane 3) or dominant negative (dn) E-cadherin (lane
4). The expression of E-cadherin, dn-E-cadherin, JNK, and -tubulin was examined by immunoblot analysis. (B) The morphology of MEF grown
to confluence was examined by phase-contrast microscopy. Representative images are illustrated. (C) MEF (5  104 cells) were plated in 24-mm
dishes and cultured for 6 days. The effect of expression of E-cadherin and dn-E-cadherin was investigated. The relative number of cells was
examined by staining with crystal violet (mean  SD; n  4). (D) Soft agar colony assays were performed using KRasG12D Trp53/ MEF and
KRasG12D Trp53/ Jnk/ MEF. The effect of expression of E-cadherin and dn-E-cadherin was investigated. The efficiency of colony formation
(%) is presented (mean  SD; n  4). Statistically significant differences are indicated (*, P  0.001; **, P  0.0001).
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(Vector Labs). Images were examined using a Leica TCS SP2 confocal micro-
scope.
DNA fragmentation assays. Genomic DNA fragmentation was measured us-
ing the cell death detection ELISAPLUS kit (Roche) according to the manufac-
turer’s recommendations (35).
Analysis of tissue sections. Histology was performed using tissue fixed in 10%
formalin for 24 h, dehydrated, and embedded in paraffin. Sections (7 	m) were
cut and stained using hematoxylin and eosin (Biocare Medical). Immunofluo-
rescence analysis was performed using deparaffinized sections treated with the
endogenous biotin-blocking kit (Invitrogen), staining (4°C, 12 h) with biotin-
conjugated anti-PCNA, and incubation (25°C, 1 h) with Alexa Fluor 633-conju-
gated streptavidin. The sections on coverslips were washed and mounted on
slides using VectaShield medium containing DAPI (Vector Labs.). Images were
examined using a Leica TCS SP2 confocal microscope.
RESULTS
Role of p53 in JNK-regulated proliferation and contact
growth inhibition. It is established that compound deficiency
of JNK1 plus JNK2 in murine embryo fibroblasts (MEF)
causes rapid p53-dependent senescence (14, 46). Indeed,
the senescence of Jnk1/ Jnk2/ MEF can be prevented
by disruption of the p53 pathway (14). We therefore pre-
pared MEF from Jnk1/ Jnk2/ Trp53/ mice (Jnk/
Trp53/ MEF). As expected, these triple-knockout Jnk/
Trp53/ MEF proliferated rapidly when cultured in vitro.
Microscopic examination of exponentially growing cultures
of WT, Trp53/, and Jnk/ Trp53/ primary MEF showed
no major differences in cell morphologies (Fig. 1A). However,
these cultures were markedly different when grown to high
density. The WT MEF formed a growth-arrested monolayer at
confluence (Fig. 1A). In contrast, the Trp53/ MEF did not
exhibit contact growth inhibition and formed densely
packed cultures with multiple layers (Fig. 1A). The
Trp53/ overgrowth phenotype was strongly suppressed in
confluent cultures of Jnk/ Trp53/ MEF (Fig. 1A). This
conclusion was confirmed by measurement of cell numbers
(Fig. 1B). Moreover, the effect of p53 deficiency to increase
cell growth in low concentrations of serum was suppressed
by JNK deficiency (Fig. 1B). To test the role of JNK in
three-dimensional cultures of p53-deficient MEF, we exam-
ined the growth of cells in soft agar. WT cells did not grow
in soft agar, but Trp53/ MEF formed small colonies (Fig.
1C and D). JNK deficiency suppressed this effect of p53
deficiency to cause growth in soft agar (Fig. 1C and D).
Together, these data demonstrate that the effect of p53
deficiency to cause loss of contact growth inhibition and
proliferation in soft agar requires JNK.
JNK is required for Ras-induced suppression of contact
growth inhibition. We employed a conditional gene ablation
strategy using primary MEF prepared from Rosa26-CreERT
/
FIG. 4. JNK suppresses stress-induced apoptosis in p53-deficient MEF. (A) MEF were exposed to the indicated doses of UV radiation. Lysates
were prepared at 4 h postirradiation, and genomic DNA fragmentation was measured by ELISA. Statistically significant differences (P  0.01)
between WT MEF and mutant MEF are indicated with an asterisk. (B) MEF were exposed to UV radiation (60 J/m2). Relative cell numbers were
measured by staining with crystal violet. The data are presented as means  standard deviations (n  3) and are representative of results from
three independent experiments. Statistically significant differences (P  0.01) between WT MEF and mutant MEF are indicated with an asterisk.
(C) MEF were exposed to UV (60 J/m2). At 6 h postirradiation, the cells were replated at the indicated dilutions. Colony formation was assessed
after 10 days in culture by staining with crystal violet. Representative images are shown. The mean number of colonies per dish (n 5) is indicated.
(D) Total cell lysates were prepared from MEF at the indicated times after exposure to UV radiation (60 J/m2). The amount of PARP and caspase
3 was assessed by immunoblot analysis using antibodies that detect both the cleaved (designated with an asterisk) and full-length forms of these
proteins. The expression of -tubulin was examined to confirm equal loading of each lane.
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Trp53LoxP/LoxP mice and Rosa26-CreERT
/ Trp53LoxP/LoxP
Jnk1LoxP/LoxP Jnk2/ mice to examine the effect of JNK plus
p53 deficiency. The effect of activated KRas was examined
using MEF prepared from mice that were heterozygous for the
LoxP-Stop-LoxP KRasG12D (KRasLSL-G12D) allele. Cre-medi-
ated recombination to ablate the floxed Trp53/Jnk1 alleles and
to express the KRasG12D allele was initiated by treatment of the
MEF with 4-hydoxytamoxifen. Comparison of Trp53/ and
Trp53/ Jnk/ MEF expressing KRasG12D demonstrated
that JNK deficiency prevented the high-density growth of the
MEF at confluence and prevented the formation of multiple
cell layers (Fig. 2A). Together, these data demonstrate that
JNK is required for Ras-induced suppression of contact growth
inhibition.
Cadherins play an important role in homotypic cellular in-
teractions (9). Expression of E-cadherin, N-cadherin, and OB-
cadherin was detected in Trp53/ and Jnk/ Trp53/ MEF
(Fig. 2B). High levels of N-cadherin were found in Trp53/
MEF (Fig. 2B). In contrast, Jnk/ Trp53/ MEF expressed
less N-cadherin and more OB-cadherin than p53/ MEF
(Fig. 2B). Studies using MEF with activated Ras demonstrated
decreased N-cadherin expression by p53/ MEF and mark-
edly increased expression of E-cadherin by Jnk/ p53/
MEF (Fig. 2B). Immunofluorescence analysis confirmed that
activated Ras reduced N-cadherin expression by Trp53/
MEF and that activated Ras increased E-cadherin expression
by Trp53/ Jnk/ MEF (Fig. 2C). These changes in cadherin
expression may contribute to the failure of Ras to suppress
contact growth inhibition of Jnk/ Trp53/ MEF compared
with that of Trp53/ MEF (Fig. 1A and 2A).
Loss of E-cadherin has been associated with reduced cell-
cell adhesion and accelerated progression to carcinoma (40).
Increased E-cadherin expression by JNK-deficient cells (Fig.
2B and C) may therefore contribute to the increased contact
growth inhibition of Ras-transformed MEF in vitro (Fig. 2A).
To test this hypothesis, we examined the effect of increased
FIG. 5. Effect of activated Ras on Trp53/ MEF and Trp53/ Jnk/ MEF. (A) MEF were exposed to 0 or 60 J/m2 UV-C, harvested
at 60 min postirradiation, and examined by immunoblot analysis using antibodies to phospho-JNK (pJNK), JNK, and -tubulin. (B) MEF
cultures were examined by phase-contrast microscopy. Representative images are illustrated. (C) The saturation density of MEF cultured
in medium (10 days) with different concentrations of serum was examined by staining with crystal violet (mean  SD; n  3). (D, E) Cell
proliferation in medium supplemented with 1% (D) or 10% (E) fetal calf serum. Relative cell number was measured by staining with crystal
violet (mean  SD; n  3).
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expression of E-cadherin in control MEF and the expression
of dominant negative (dn) E-cadherin in JNK-deficient
MEF (Fig. 3A). These changes in E-cadherin did not alter
cell morphology at confluence (Fig. 3B) or proliferation
(Fig. 3C). However, increased expression of E-cadherin did
suppress the growth of control Ras-transformed MEF in soft
agar (Fig. 3D). Ras-transformed JNK-deficient MEF grew
poorly in soft agar, but expression of dn-E-cadherin did not
increase soft agar growth (Fig. 3D). Together, these data
indicate that E-cadherin expression may only partially con-
tribute to the phenotype of JNK-deficient MEF transformed
by Ras.
The mechanism that accounts for the increased expression
of E-cadherin by Ras-transformed JNK-deficient MEF is un-
clear. We detected increased expression of E-cadherin (Cdh1)
mRNA by Ras-transformed JNK-deficient MEF compared
with that by Ras-transformed control MEF (Fig. 2D). This
observation indicates that JNK may function to repress E-
cadherin gene expression. Previous studies have established
that repressors, including Snail (Snai1) and Slug (Snai2),
downregulate E-cadherin expression (4, 8, 24). Indeed, we
found that the increased expression of E-cadherin by Ras-
transformed JNK-deficient MEF was associated with signifi-
cantly decreased expression of Slug (Fig. 2D). It is therefore
possible that JNK-regulated expression of Slug may contribute
to increased E-cadherin expression by Ras-transformed JNK-
deficient MEF.
Role of p53 in JNK-mediated apoptosis. It is established that
the JNK signaling pathway contributes to the apoptotic re-
sponse to some insults by activating the intrinsic (mitochon-
drial) pathway (46). The mechanism is mediated, in part, by
phosphorylation of members of the Bcl2-related protein fam-
ily, including Bim, Bmf, and Mcl-1 (26, 27, 38). This signaling
pathway may influence tumor development (49).
A role for p53 in JNK-dependent apoptosis has been pro-
posed (7, 20, 21). To test the requirement of p53 in JNK-
mediated apoptosis, we examined the effect of UV radiation on
JNK- and p53-deficient MEF (Fig. 4). UV-stimulated genomic
DNA fragmentation assays demonstrated that both p53/
MEF and Jnk/ Trp53/ MEF exhibited resistance to UV
radiation (Fig. 4A). However, time course analysis of cell sur-
vival demonstrated that Trp53/ MEF were partially resistant
to UV radiation and that Jnk/ Trp53/ MEF exhibited
significantly increased resistance to UV radiation (Fig. 4B).
This conclusion was confirmed by the analysis of colony for-
mation following exposure to UV radiation (Fig. 4C). These
data demonstrate that JNK can regulate apoptosis indepen-
dently of p53. To obtain biochemical evidence to support this
FIG. 6. Ras-mediated signal transduction in Trp53/ MEF and Trp53/ Jnk/ MEF. (A) MEF were exposed to 0 or 60 J/m2 UV-C and
harvested at 60 min postirradiation. The amounts of phospho-p38 MAP kinase (p-p38), phospho-ERK (pERK), phospho-JNK (pJNK), and
phospho-Ser473-AKT (pAKT) were measured by multiplexed ELISA (mean  SD; n  3). (B) ROS accumulation was examined by measurement
of fluorescence intensity in studies of MEF stained with H2DCFDA. The relative fluorescence intensity is indicated in the lower right corner of
each panel. (C) The effect of rotenone and diphenyleneiodonium chloride (DPI) on ROS production by Ras-transformed Trp53/ MEF was
examined by measurement of mean fluorescence intensity (mean  SD; n  3). Statistically significant differences (P  0.05) are indicated with
an asterisk. (D) The expression of Nox4 and p22phox mRNA by Ras-transformed Trp53/ MEF and Trp53/ Jnk/ KRasG12D MEF was
examined by quantitative RT-PCR assays. The data presented are normalized for the amount of Gapdh mRNA in each sample (mean  SD; n 
3 samples). Statistically significant differences (P  0.01) are indicated with an asterisk.
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conclusion, we examined UV-stimulated activation of caspase
3 and cleavage of the caspase substrate PARP (Fig. 4D). We
found that p53 deficiency did not prevent caspase 3 activation,
but caspase 3 activation was strongly suppressed in Jnk/
Trp53/ MEF. These data demonstrate that p53 is not
required for JNK-dependent apoptosis. JNK deficiency may
therefore contribute to tumor development in a p53-defi-
cient genetic background by suppression of stress-induced
apoptosis.
JNK deficiency suppresses Ras-stimulated transformation
in vitro. The Trp53/ and Jnk/ Trp53/ MEF represent
genetically defined primary cells that can be employed to test
the requirement of JNK for transformation by Ras in vitro (Fig.
4). Control studies confirmed the presence of a functional JNK
signaling pathway in Trp53/ MEF but not in Jnk/
Trp53/ MEF (Fig. 5A). Microscopic examination demon-
strated that activated Ras caused p53/ MEF to exhibit a
spindle-shaped morphology, but this morphological change
was reduced in Jnk/ p53/ MEF (Fig. 5B). Measurement
of growth in response to different concentrations of serum
demonstrated that activated Ras increased the saturation
density of both Trp53/ and Jnk/ Trp53/ MEF, al-
though the JNK-deficient MEF exhibited less growth (espe-
cially in low serum concentrations) than p53/ MEF (Fig.
5C). This conclusion was confirmed by direct measurement
of cell proliferation in low (1%) and high (10%) serum
concentrations (Fig. 5D and E).
Since JNK deficiency did not prevent Ras-stimulated growth
(Fig. 5), we questioned whether the loss of JNK might influ-
ence other signal transduction pathways in MEF with activated
Ras. No significant differences in the activation of ERK, p38
MAP kinase, and AKT were detected when Trp53/ and
Jnk/ Trp53/ MEF were compared (Fig. 6A). However, we
detected reduced levels of reactive oxygen species (ROS) in
Jnk/ Trp53/ MEF compared with those in Trp53/ MEF
(Fig. 6B). The ROS in Trp53/ MEF with activated Ras was
suppressed by diphenyleneiodonium chloride (DPI), an inhib-
itor of NADPH oxidases (Nox) enzymes, but not by the mito-
chondrial electron transport inhibitor rotenone (Fig. 6C).
These data are consistent with Nox-dependent, rather than
mitochondrion-dependent, ROS accumulation (31, 51). Nox1
and Nox4 have been implicated in ROS production by MEF
(17). JNK deficiency caused no change in the expression of
Nox1 (data not shown), but JNK deficiency did cause re-
duced expression of Nox4 (Fig. 6D). Expression of the Nox
enzyme subunit p22phox was not altered by JNK deficiency
(Fig. 6D).
ROS production has been implicated in tumorigenesis (44).
The levels of ROS detected in Trp53/ MEF being greater
than those in Jnk/ Trp53/ MEF suggests that JNK defi-
ciency may alter the tumorigenic potential of these MEF with
activated Ras. To test this prediction, we examined the growth
of these MEF in soft agar assays in vitro. We found that acti-
vated Ras caused growth of large colonies of Trp53/ MEF in
soft agar, but activated Ras did not cause the growth of large
Jnk/ Trp53/ MEF colonies in soft agar (Fig. 7A and B).
Retroviral transduction of Nox4 did not rescue the defect in
soft agar growth or contact growth inhibition detected in cul-
tures of Ras-transformed Jnk/ Trp53/ MEF (data not
shown). This observation demonstrates that reduced expres-
sion of Nox4 is not sufficient to account for the phenotype of
Ras-transformed JNK-deficient MEF.
To test the effect of JNK deficiency on tumor formation in
vivo, we examined the subcutaneous growth of MEF with ac-
tivated Ras in syngeneic mice. We found that Ras-transformed
Trp53/ MEF formed tumors, but this growth was strongly
suppressed by JNK deficiency (Fig. 7C and D). Together, these
data demonstrate that JNK is required for Ras-induced trans-
formation of p53-deficient MEF in vitro.
JNK deficiency suppresses Ras-induced lung tumor forma-
tion in vivo. In vitro studies suggest that JNK is required for
Ras-stimulated transformation (Fig. 7). To test whether JNK
contributes to Ras-stimulated transformation in vivo, we ex-
amined the effect of activated Ras in an established model of
lung tumorigenesis (29). Lung-specific expression of KRasG12D
was studied using nasal instillation of adenovirus-Cre (29). We





 (control) mice and in mice with conditional compound
JNK deficiency (Jnk1LoxP/LoxP Jnk2/). Expression of
KRasG12D caused lesions in the lungs, including atypical ade-
nomatous hyperplasia, epithelial hyperplasia of bronchioles,
and adenomas (Fig. 8A and B). Comparison of control mice
with JNK-deficient mice demonstrated that the number of
hyperplastic lesions and adenomas was greatly reduced in the
FIG. 7. JNK is required for colony formation in soft agar and
tumor formation in vivo. (A, B) Ras-transformed MEF and (Trp53/
Jnk/ MEF were treated with 1 	M 4-hydroxy-tamoxifen (24 h). The
MEF were plated in soft agar and incubated for 2 weeks. (A) Repre-
sentative images of colonies formed by the MEF are illustrated. The
number of soft agar colonies per plate was counted (mean  SD; n 
6) (B). Statistically significant differences (P  0.001) are indicated
with an asterisk. (C, D) MEF were injected subcutaneously in the flank
of host mice. (C) Palpable tumor nodules were measured. (D) The
mice were euthanized at day 21 postinjection, and the tumor mass
(mean SD; n 10) was measured. Statistically significant differences
(P  0.001) are indicated with an asterisk.
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JNK-deficient mice (Fig. 8C and D). Immunofluorescence
analysis of lung sections demonstrated that JNK deficiency
caused a marked decrease in staining for the proliferation
marker PCNA (Fig. 8E). No major differences in apoptosis
markers (caspase 3 activation and PARP cleavage) between
control and JNK-deficient lungs were detected (Fig. 8F).
These data demonstrate that JNK is required for the effi-
cient formation of Ras-induced lesions in the lung. The
major role of JNK is reflected by increased proliferation
rather than altered apoptosis.
The low level of lung tumorigenesis detected in JNK-defi-
cient mice suggests that JNK may not be essential for Ras-
induced lung cancer. These tumors may represent JNK-inde-
pendent formation of lung cancer. Alternatively, these tumors
may arise because of incomplete Cre-mediated ablation of Jnk
genes. Indeed, the possible presence of incomplete gene abla-
tion in this model of KRas-induced lung cancer is consistent
with previous reports using Rac1LoxP/LoxP mice (33). We tested
whether incomplete Jnk gene ablation might contribute to the
low level of tumorigenesis in JNK-deficient mice by genotype
analysis of genomic DNA isolated from these tumors. This
analysis demonstrated that all of the JNK-deficient lung tu-
mors examined retained a Jnk1LoxP allele (Fig. 9). Indeed,
immunofluorescence analysis of the phosphorylation of the
FIG. 8. JNK is required for Ras-induced lung tumorigenesis. (A) KRas
/LSL-G12D mice (control KRasG12D mice) and KRas
/LSL-G12D Jnk1LoxP/
LoxP Jnk2/ mice (KRasG12D Jnk/ mice) were exposed to adenovirus-Cre by nasal instillation. Lung tumors were detected by examination of the
lungs at 12 weeks postinfection. (B) Lung tissue sections prepared from control KRasG12D mice and KRasG12D Jnk/ mice at 4 weeks and 8 weeks
postinfection were stained with hematoxylin and eosin. (C) The number of hyperplastic lesions per tissue section was measured at 4, 8, and 12
weeks postinfection. Significant differences between control and JNK-deficient tumors are indicated with an asterisk (P  0.05; n  10). (D) The
number of adenomas (0.5 mm) per tissue section was measured at 4, 8, and 12 weeks postinfection. Significant differences between control and
JNK-deficient tumors are indicated with an asterisk (P 0.05; n 10). (E) Lung sections were stained with an antibody to the proliferation marker
PCNA (red). DNA was stained with DAPI (blue). (F) Lung extracts prepared from mice treated without adenovirus-Cre (control and JnkLoxP/LoxP)
and with adenovirus-Cre (KRasG12D and KRasG12D Jnk/) at 12 weeks postinfection were examined by immunoblot analysis using antibodies to
detect PCNA, cleaved PARP, caspase 3 (Casp. 3), cleaved caspase 3 (Casp. 3*), and -tubulin.
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JNK substrate c-Jun on Ser63 demonstrated that the JNK-
deficient tumors retained a functional JNK signaling pathway
(Fig. 9). We did not find in JNK-deficient mice any tumors that
lacked expression of the Jnk1LoxP allele or phosphorylation of
the JNK substrate c-Jun. These data indicate that JNK may be
essential for KRas-induced lung tumorigenesis.
DISCUSSION
This study demonstrates that JNK can play a major role in
Ras-induced tumor formation. Specifically, JNK is essential for
transformation of primary p53/ MEF by activated Ras in
vitro. Moreover, JNK is required in a mouse model of Ras-
induced lung tumor formation in vivo. Together, these data
provide strong evidence that the JNK signaling pathway may
contribute to the development of cancer.
Further studies are needed to identify the signaling pathway
that leads to Ras-induced JNK signaling. A recent study estab-
lished that Rac1 is required for Ras-induced lung tumor for-
mation (33). Since Rac1 can cause JNK activation (3, 12, 37),
it is possible that this role of Rac1 may reflect a requirement of
Rac1 for JNK activation in this model of Ras-induced lung
tumorigenesis. Targets of Rac1 that may mediate JNK pathway
activation include members of the mixed-lineage protein ki-
nase family (22).
Additional studies are required to identify JNK substrates
that are relevant to lung tumorigenesis. It is possible that AP1
family transcription factors, which are activated by JNK, may
contribute to Ras-induced lung tumor formation. However,
many other targets of JNK signaling, in both the cytoplasm and
the nucleus, may contribute to JNK-dependent tumorigenesis
(48). Detailed analysis of these JNK substrates is required to
identify those relevant to lung tumorigenesis.
JNK prevents contact growth inhibition. JNK may contrib-
ute to dysregulated cellular proliferation by interfering with
contact growth inhibition. Trp53/ and Trp53/ KRasG12D
primary MEF exhibit defects in contact growth inhibition and
form multiple layers when grown to confluence (Fig. 1A and
2A). In contrast, compound deficiency of Jnk1 plus Jnk2 pre-
vents the overgrowth phenotype of both Trp53/ and
Trp53/ KRasG12D primary MEF (Fig. 1A and 2A). This
effect of JNK correlates with altered expression of the cadherin
family of adhesion proteins (Fig. 2B and C). Strikingly, Ras-
transformed Trp53/ Jnk/ primary MEF express high levels
of E-cadherin (Fig. 2B and C). This expression of E-cadherin
may contribute to increased intercellular adhesion. Moreover,
in the context of Ras-induced epithelial cell tumorigenesis,
increased E-cadherin expression might decrease epithelial-
mesenchymal transition (EMT) and progression to carcinoma
(5). Indeed, it is established that EMT of lung epithelium is
suppressed by JNK deficiency (1). These actions of JNK to
decrease the intercellular adhesion of cells expressing
KRasG12D may contribute to tumor formation.
JNK and the tumor microenvironment. This study has fo-
cused on the role of JNK in tumor cells. However, JNK may
also play roles within the tumor microenvironment, including
expression of cytokines/growth factors (15) and the function of
the innate and adaptive immune systems (15, 23, 45). Thus, the
finding that Jnk1/ mice exhibit decreased (and Jnk2/ mice
exhibit increased) carcinogen-induced skin cancer compared
with wild-type mice (11, 42) may be explained, in part, by the
opposite effects of JNK1 and JNK2 deficiency on CD8 T cell-
mediated tumor immunosurveillance (23, 45). Moreover, the
effects of JNK1 deficiency to suppress carcinogen-induced hepa-
tocellular carcinoma (28) may be accounted for, in part, by
decreased expression of inflammatory cytokines (e.g., interleu-
kin 6 [IL-6] and tumor necrosis factor [TNF]) by hepatic innate
FIG. 9. Analysis of lung tumors detected in JNK-deficient mice.
Nasal instillation of adenovirus-Cre was performed using control
KRas
/LSL-G12D mice and JNK-deficient Jnk1LoxP/LoxP Jnk2/
KRas
/LSL-G12D mice.Cre-mediated ablation of theLoxP-Stop-LoxP cassette
causes expression of KRasG12D in the lung epithelium. (A) Genomic
DNA was isolated from individual lung tumors in Jnk1LoxP/LoxP
Jnk2/ KRas
/LSL-G12D mice and examined by PCR analysis to detect
the KRas
, KRasG12D, and KRasLSL-G12D alleles (top) and the Jnk1LoxP
and Jnk1 alleles (bottom). Control (Con) studies were performed
using equal mixtures of genomic DNA isolated from normal lung and
from lung tumors of Jnk1LoxP/LoxP Jnk2/ KRas
/LSL-G12D mice. These
data confirm efficient deletion of the LoxP-Stop-LoxP cassette from the
KRasG12D gene and retention of the Jnk1LoxP allele in the JNK-defi-
cient tumors. (B) The structures of the wild-type KRas (WT),
KRasG12D, Jnk1LoxP, and Jnk1 genes are illustrated schematically.
Amplimers employed for PCRs designed to distinguish between these
genes are indicated. (C) Sections of lung tumors were stained using an
antibody to phospho-Ser63–c-Jun and DAPI and examined by fluores-
cence microscopy (left). The fluorescent images were merged with
images obtained using differential interference contrast microscopy
(right). Ser63 is a phosphorylation site of c-Jun by JNK. These data
demonstrate that lung tumors in JNK-deficient mice retain a func-
tional JNK signaling pathway.
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immune cells (15). These considerations indicate that a full
understanding of the role of JNK in cancer should take ac-
count of JNK functions in both tumor cells and the tumor
microenvironment.
JNK and tumor suppression. The results of this study dem-
onstrate that Ras-induced transformation of primary MEF and
Ras-induced lung tumor formation requires JNK. However,
these data do not exclude the possibility that JNK may also
contribute to tumor suppression. Indeed, published studies
have implicated JNK in both tumor formation and tumor sup-
pression (16, 49). Precedent for this type of dual activity during
tumor development is provided by the transforming growth
factor  (TGF-) pathway (43). Roles of the JNK pathway in
tumor suppression most often correlate with late-stage tumor
metastasis (49). Indeed, studies of human cancer genetics and
biochemical analysis of human tumor-derived cell lines support
the conclusion that the JNK signal transduction pathway may
contribute to metastasis suppression (49). Moreover, Ras
transformation of established cell lines demonstrates that loss
of JNK can cause increased metastatic potential (32). Further
studies will be required to formally test the hypothesis that
JNK may act as a suppressor of late-stage tumor development
in vivo. In contrast, this study demonstrates that JNK is re-
quired for early stage Ras-induced tumor formation in vitro
and in vivo.
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